BlossomHill Therapeutics
Dr. Jesse Shao is the Vice President of CMC at BlossomHill Therapeutics. He has over 25 years of experience in Pharmaceutical R&D, notably in the area of controlled-release drug delivery. Dr. Shao has held various technical and leadership positions with increasing responsibilities at Schering-Plough, Pfizer, Arena Pharmaceuticals, and FibroGen. Prior to joining BlossomHill, he was Executive Director at FibroGen, where he contributed to the approval and launch of EVRENZOTM in the EU, Japan and China. At Arena Pharmaceuticals, he led the successful drug product technology transfer, approval and launch of BELVIQ® and BELVIQ XR®.
Dr. Shao received his B.S. in Pharmacy from Peking University, M.S. in Physical Pharmacy from the University of Cincinnati, and Ph.D. in Industrial and Physical Pharmacy from Purdue University. Additionally, Dr. Shao is a registered Pharmacist in the state of New Jersey, an inventor of numerous patents, and has authored over 30 publications.
This person is not in any offices
BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.